The estimated Net Worth of Nicholas Borys is at least $895 mil dollars as of 12 December 2011. Nicholas Borys owns over 5,000 units of Imunon Inc stock worth over $69,947 and over the last 16 years he sold CLSN stock worth over $0. In addition, he makes $824,966 as Senior Vice President and Chief Medical Officer at Imunon Inc.
Nicholas has made over 3 trades of the Imunon Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of CLSN stock worth $10,000 on 12 December 2011.
The largest trade he's ever made was buying 6,000 units of Imunon Inc stock on 19 November 2008 worth over $15,000. On average, Nicholas trades about 602 units every 53 days since 2008. As of 12 December 2011 he still owns at least 35,687 units of Imunon Inc stock.
You can see the complete history of Nicholas Borys stock trades at the bottom of the page.
Dr. Nicholas Borys, M.D., is Senior Vice President and Chief Medical Officer of Celsion Corporation., since October 1, 2007. Dr. Borys joined Celsion on October 1, 2007 as Vice President and Chief Medical Officer of the Company and was promoted to Senior Vice President in June 2014. In this position, Dr. Borys manages the clinical development and regulatory programs for Celsion. Dr. Borys has over 20 years of experience in all phases of pharmaceutical development with a focus on oncology. Immediately prior to joining Celsion, Dr. Borys served as Chief Medical Officer of Molecular Insight Pharmaceuticals, Inc., a molecular imaging and nuclear oncology pharmaceutical company, from 2004 until 2007. From 2002 until 2004 he served as the Vice President and Chief Medical Officer of Taiho Pharma USA, a Japanese start-up oncology therapeutics company. Prior to that he held increasingly senior positions at Cytogen Corporation, Anthra Pharmaceuticals, Inc., Amersham Healthcare, Inc. and Hoffmann La-Roche Inc. Dr. Borys obtained his premedical degree from Rutgers University and holds an M.D. degree from American University of the Caribbean.
As the Senior Vice President and Chief Medical Officer of Imunon Inc, the total compensation of Nicholas Borys at Imunon Inc is $824,966. There are 2 executives at Imunon Inc getting paid more, with Michael Tardugno having the highest compensation of $1,694,790.
Nicholas Borys is 55, he's been the Senior Vice President and Chief Medical Officer of Imunon Inc since 2014. There are 12 older and no younger executives at Imunon Inc. The oldest executive at Imunon Inc is Michael H. Tardugno, 70, who is the Exec. Chairman, Pres & CEO.
Nicholas's mailing address filed with the SEC is 10220-L OLD COLUMBIA ROAD, , COLUMBIA, MD, 21046.
Over the last 17 years, insiders at Imunon Inc have traded over $895,739 worth of Imunon Inc stock and bought 973,579 units worth $2,229,348 . The most active insiders traders include Gary W Pace, Max Link, eSean F. Moran. On average, Imunon Inc executives and independent directors trade stock every 38 days with the average trade being worth of $22,407. The most recent stock trade was executed by Michael H Tardugno on 12 April 2022, trading 4,000 units of CLSN stock currently worth $14,120.
Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection.
Imunon Inc executives and other stock owners filed with the SEC include: